Plain English Summary
PYY 3-36 is a gut-derived hormone that acts as a signaling molecule to regulate appetite, satiety, and potentially drug-seeking behavior. Research focuses on its role in metabolic health, specifically as a potential adjunctive therapy to GLP-1 agonists for obesity management, though current clinical evidence suggests challenges with tolerability.
What People Use It For
Side Effects & Risks
Common Side Effects
References
- 1https://pubmed.ncbi.nlm.nih.gov/28003328/
- 2https://pubmed.ncbi.nlm.nih.gov/40629530/
- 3https://pubmed.ncbi.nlm.nih.gov/37572954/
- 4https://pubmed.ncbi.nlm.nih.gov/37001706/
- 5https://pubmed.ncbi.nlm.nih.gov/38542814/
- 6https://pubmed.ncbi.nlm.nih.gov/25527432/
- 7https://pubmed.ncbi.nlm.nih.gov/26006332/
- 8https://pubmed.ncbi.nlm.nih.gov/12167864/
Researchers also explore
Glucose-dependent insulinotropic polypeptide (GIP)
GIP is a naturally occurring incretin hormone secreted by the intestine after nutrient ingestion. It plays a foundational role in metabolic regulation by stimulating insulin secretion, modulating fat storage, and signaling satiety in the brain. While historically overshadowed by GLP-1, it has recently become a key component in advanced weight loss and diabetes treatments like dual-agonist therapies.
GIP (Glucose-dependent Insulinotropic Polypeptide)
GIP is an endogenous incretin hormone released from the gut after nutrient intake. It plays a critical role in glucose metabolism by stimulating insulin secretion in a glucose-dependent manner. While historically studied for its insulinotropic effects, modern research focuses on its systemic roles in adipose tissue, bone remodeling, and the central nervous system, particularly when combined with GLP-1 for metabolic therapies.
Glucose-dependent insulinotropic polypeptide (GIP)
GIP is an incretin hormone secreted by the intestine that plays a key role in glucose metabolism and energy homeostasis. While traditionally recognized for its role in stimulating insulin secretion in response to nutrient intake, recent research highlights its involvement in lipid metabolism, bone health, and neurological function. It is currently a focal point of therapeutic development in combination with GLP-1 agonists for treating obesity and metabolic disease.
Glucose-dependent insulinotropic polypeptide (GIP)
GIP is an incretin hormone produced by the intestine that plays a vital role in regulating glucose levels, insulin secretion, fat metabolism, and bone health. While historically recognized for its insulinotropic effects, modern research focuses on its role alongside GLP-1 in treating metabolic disorders such as obesity and type 2 diabetes.
Researcher Sentiment
No votes yet — be the first
Educational Content Only
This is not medical advice. Always consult a licensed healthcare provider before using any compound. No dosing or sourcing guidance is provided.
